Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Ranger Investment Management L.P.

Ranger Investment Management L.P. reduced its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 2.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 72,476 shares of the company’s stock after selling 1,595 shares during the period. Medpace makes up approximately 1.5% of Ranger Investment Management L.P.’s portfolio, making the stock its 28th biggest position. Ranger Investment Management L.P. owned about 0.23% of Medpace worth $24,079,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently bought and sold shares of the stock. Pallas Capital Advisors LLC lifted its holdings in shares of Medpace by 179.7% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after acquiring an additional 2,101 shares during the last quarter. Barclays PLC lifted its stake in Medpace by 71.9% during the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock worth $6,603,000 after purchasing an additional 8,275 shares in the last quarter. Sanctuary Advisors LLC boosted its position in shares of Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock worth $1,738,000 after buying an additional 844 shares during the period. SYM FINANCIAL Corp acquired a new stake in shares of Medpace in the fourth quarter valued at $320,000. Finally, Tokio Marine Asset Management Co. Ltd. purchased a new stake in shares of Medpace in the 4th quarter valued at $9,335,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

MEDP has been the subject of a number of research analyst reports. Robert W. Baird raised their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Leerink Partnrs raised shares of Medpace to a “hold” rating in a research note on Monday, March 24th. Finally, Leerink Partners began coverage on shares of Medpace in a research note on Monday, March 24th. They set a “market perform” rating and a $330.00 target price on the stock. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $376.30.

Medpace Trading Down 4.4 %

Medpace stock opened at $277.23 on Wednesday. The company has a fifty day simple moving average of $327.67 and a 200-day simple moving average of $335.73. The stock has a market cap of $8.38 billion, a P/E ratio of 21.95, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46. Medpace Holdings, Inc. has a 12-month low of $269.36 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.